New Pill Cuts 'Bad' Cholesterol by 60%, Offering New Hope for Cardiovascular Disease Treatment
A large phase three clinical trial reveals that a new experimental oral medication called enlicitide can reduce low-density lipoprotein (LDL, or 'bad' cholesterol) levels by up to 60%, rivaling the efficacy of powerful existing injectable therapies. Led by UT Southwestern Medical Center, this study offers the potential for a convenient and highly effective new option for millions of patients who struggle to control their cholesterol with current treatments, significantly lowering the risk of heart attacks and strokes.